Evidence map›Paper›PMID 30648052›Full record

ArticleCureus2018

Reversible Left Ventricular Systolic Dysfunction Secondary to Pazopanib.

Kushani Gajjar, Kathir Balakumaran, Agnes S Kim

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 76% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Kushani GajjarInternal Medicine, University of Connecticut Health Center, Farmington, USA.
Kathir BalakumaranCardiology, University of Connecticut Health Center, Farmington, USA.
Agnes S KimCardiology, University of Connecticut Health Center, Farmington, USA.
UConn Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pazopanib is a tyrosine kinase inhibitor used for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma. We describe a case report of a patient with spindle cell sarcoma who developed severe left ventricular systolic dysfunction after starting pazopanib therapy with subsequent recovery of left ventricular ejection fraction upon stopping therapy.

Indexed as

cardiomyopathycardio-oncologycardiotoxicityoncologypazopanibtyrosine kinase inhibitorsvascular-endothelial growth factor

Identifiers

PMID30648052
PMCPMC6318145
OpenAlexW2899501539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.